Pa-thai T. Yenchitsomanus

2 Wanglang Road
Bangkok Noi, 10700, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 167 publications

Triple-costimulatory GD2-CAR T cells incorporating CD28, 4-1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models.

Triple-costimulatory GD2-CAR T cells incorporating CD28, 4-1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 21, 2026

Dual bispecific protein engager-armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma.

Dual bispecific protein engager-armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 14, 2026

αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma.

αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: March 10, 2026

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 05, 2026

HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients.

HLA class I-specific nucleolin peptides induce therapeutic T cells in triple-negative breast cancer patients.

Journal: International journal of biological sciences

Published: January 30, 2026

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.

Journal: BMC medicine

Published: December 30, 2025

Intravitreal GD2-Specific Chimeric Antigen Receptor T-Cell Therapy for Refractory Retinoblastoma.

Intravitreal GD2-Specific Chimeric Antigen Receptor T-Cell Therapy for Refractory Retinoblastoma.

Journal: Pediatric blood & cancer

Published: November 02, 2025

Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors.

Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors.

Journal: Scientific reports

Published: November 02, 2025

Next-generation CAR T cells targeting integrin αvβ6 and PD-L1 to enhance immunotherapy for cholangiocarcinoma.

Next-generation CAR T cells targeting integrin αvβ6 and PD-L1 to enhance immunotherapy for cholangiocarcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 02, 2025

Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity.

Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 01, 2025

Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma.

Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma.

Journal: Anticancer research

Published: September 05, 2025

Engineering a fifth-generation CAR T cells to overcome PD-L1-mediated immunosuppression in lung cancer.

Engineering a fifth-generation CAR T cells to overcome PD-L1-mediated immunosuppression in lung cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 02, 2025

Showing 1-12 of 167

Last Updated: 09/26/2026